A comparison of fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies

Pharmacoepidemiology and Drug Safety

Volumn 6, Issue 4, 1997, Pages 235-246

  Mackay, Fiona J ^a   Dunn, Nicholas R ^a   Wilton, Lynda V ^a   Pearce, Gillian L ^a   Freemantle, Shayne N ^a   Mann, Ronald D ^a  

^a DRUG SAFETY RESEARCH UNIT   (United Kingdom)

Author keywords

Cohort studies; Fluoxetine; Fluvoxamine; Observational studies; Paroxetine; Pharmacovigilance; Post marketing surveillance; Prescription event monitoring; Sertraline

Indexed keywords

FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ABDOMINAL PAIN; ADULT; ADVERSE DRUG REACTION; AGED; ANXIETY; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIARRHEA; DROWSINESS; DRUG MONITORING; DRUG SURVEILLANCE PROGRAM; DYSPEPSIA; FEMALE; HEADACHE; HUMAN; INSOMNIA; LASSITUDE; MAJOR CLINICAL STUDY; MALAISE; MALE; NAUSEA; PHARMACOEPIDEMIOLOGY; PREGNANCY; PRESCRIPTION; PRIORITY JOURNAL; SEDATION; SUICIDE; TREMOR; VERTIGO; VOMITING;

EID: 0030769245     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1557(199707)6:4<235::AID-PDS293>3.0.CO;2-3     Document Type: Article

References (16)

1. Song, F., Freemantle, N., Sheldon, T. A., et al. Selective serotonin reuptake inhibitors: metaanalysis of efficacy and acceptability. British Medical Journal 1993; 306: 683-687.
2. Montgomery, S. A. The benefits and risks of 5-HT uptake inhibitors in depression. British Journal of Psychiatry 1988; 153 (Suppl. 13): 7-10.
3. Grimsley, S. R. and Jann, M. W. Paroxetine, sertraline and fluvoxamine: new selective serotonin reuptake inhibitors. Clinical Pharmacology 1992; 11: 930-957.
4. Committee on Safety of Medicines. Medicines Control Agency. Dystonia and withdrawal symptoms and paroxetine. Current Problems 1993; 19: 1.
5. Leonard, B. E. Pharmacological differences of serotonin reuptake inhibitors and possible clinical relevance. Drugs 1992; 43 (Suppl. 2): 3-10.
6. Edwards, J. G. Drug choice in depression. Selective serotonin reuptake inhibitors or tricyclic antidepressants? CNS Drugs 1995; 4(2): 141-159.
7. Mann, R. D. Epidemiologic study systems: Prescription-Event Monitoring in the UK. Southampton Medical Journal 1994; 10: 12-17.
8. Inman, W. H. W. An introduction to Prescription-Event Monitoring. In: Adverse Drug Reactions. Mann, R. D. (Ed.) Parthenon Publishing, Carnforth UK, 1987, pp. 177-199.
9. British National Formularies 1988-1992 (Numbers 15-24).
10. Inman, W. H. W. Postmarketing surveillance of adverse drug reactions in general practice; II: Prescription-event monitoring at the University of Southampton. British Medical Journal 1981; 282: 1216-1217.
11. Rawson, N. S. B., Pearce, G. L. and Inman, W. H. W. Prescription-event monitoring: methodology and recent progress. Journal of Clinical Epidemiology 1990; 43: 509-522.
12. Mann, R. D. Prescription-event monitoring: its role in ensuring new drug safety. Prescriber March 1996; 7: 102-104.
13. Wilton, L. V., Pearce, G. L. and Mann, R. D. A comparison of ciprofloxacin, norfloxacin, ofloxacin, azithromycin and cefixime examined by observational cohort studies. British Journal of Clinical Pharmacology 1996; 41: 277-284.
14. Peet, M. Induction of mania with selective serotonin reuptake inhibitors and tricyclic anti-depressants. British Journal of Psychiatry 1994; 164: 549-550.
15. Feder, R. Fluoxetine induced mania. Journal of Clinical Psychiatry 1990; 51: 524-525.
16. Teicher, M. H., Glod, C. and Cole, J. O. Emergence of intense suicidal preoccupation during Fluoxetine treatment. American Journal of Psychiatry 1990; 147: 207-210.